---
title: "Targeting the NTCP–EGFR Complex to Block HBV and HDV Entry"
id: "pubmed-43008022"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-43008022"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/43008022/"
doi: "10.1073/pnas.2603986123"
published_at: "2026-11-17T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Targeting the NTCP–EGFR Complex to Block HBV and HDV Entry
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-43008022
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/43008022/)
- **DOI:** [10.1073/pnas.2603986123](https://doi.org/10.1073%2Fpnas.2603986123)
- **Published At:** 2026-11-17T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- Investigators developed an in vitro assay to measure the interaction between **NTCP** (sodium taurocholate cotransporting polypeptide) and **EGFR** (epidermal growth factor receptor). - Using that assay, the team identified an oxysterol-derived compound, **Oxy229**, that disrupted the NTCP–EGFR molecular interaction. - **Oxy229** selectively inhibited **HBV** and **HDV** infection of HepG2-NTCP cells and primary human hepatocytes in culture. - Mechanistic experiments showed the compound impaired relocalization of the HBV–NTCP complex from the plasma membrane into intracellular vesicles, a step in viral entry. - The study reported that **Oxy229** did not impair NTCP’s bile acid transport activity nor did it block EGFR downstream signaling through Ras–MAPK or PI3K–Akt pathways, indicating selective antiviral activity without overt blockade of those host functions. - Analogue screening identified **Oxy283**, a derivative that disrupted both the NTCP–EGFR interaction and NTCP multimerization, and which demonstrated increased anti-HBV potency compared with Oxy229. - Data indicated that formation of an NTCP-centered receptor complex is functionally important for HBV/HDV entry into hepatocytes. - The source did not report in vivo efficacy, clinical development steps, or safety data beyond the in vitro selectivity assays described in the abstract.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/43008022/#article-details) ### NIH Websites Are Changing * [Get the Latest Updates and FAQs on the transition](https://www.nih.gov/web-modernization) * Per [Executive Order 14434](https://www.whitehouse.gov/presidential-actions/2026/09/inaugurating-the-era-of-super-intelligence/), federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition. ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F43008022%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/43008022/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/43008022/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/43008022/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/a447896c-976f-490b-b86b-2668b65114a8/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/43008022/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/43008022/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/43008022/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F43008022%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F43008022%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/43008022/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/43008022/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/43008022/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/43008022/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Full text links [![Atypon full text link](https://cdn.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--www.pnas.org-pb-assets-images-pubmed-pnas-pubmed-oa.png) Atypon ](https://www.pnas.org/doi/10.1073/pnas.2603986123?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed "See full text options at Atypon") [ Full text links ](https://pubmed.ncbi.nlm.nih.gov/43008022/) ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/43008022/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Experimental Resource Linked Discoveries ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/43008022/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/43008022/#abstract) * [ Conflict of interest statement ](https://pubmed.ncbi.nlm.nih.gov/43008022/#conflict-of-interest) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/43008022/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/43008022/#substances) * [Related information](https://pubmed.ncbi.nlm.nih.gov/43008022/#related-links) * [ Grants and funding ](https://pubmed.ncbi.nlm.nih.gov/43008022/#grants) * [ LinkOut - more resources ](https://pubmed.ncbi.nlm.nih.gov/43008022/#linkout) Title & authors Abstract Conflict of interest statement MeSH terms Substances Related information Grants and funding LinkOut - more resources Proc Natl Acad Sci U S A Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Proc+Natl+Acad+Sci+U+S+A%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Proc+Natl+Acad+Sci+U+S+A%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43008022/) . 2026 Nov 17;123(46):e2603986123. doi: 10.1073/pnas.2603986123. Epub 2026 Nov 10. # Disruption of the NTCP-EGFR receptor complex as a strategy for selective inhibition of hepatitis B and D virus entry [Atsuto Kusunoki](https://pubmed.ncbi.nlm.nih.gov/?term=Kusunoki+A&cauthor_id=43008022)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/43008022/#full-view-affiliation-1 "Graduate School of Infection Control Sciences, Kitasato University, Tokyo 108-8641, Japan.")[ 2 ](https://pubmed.ncbi.nlm.nih.gov/43008022/#full-view-affiliation-2 "Department of Drug Development, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo 162-8640, Japan."), [Kaho Shionoya](https://pubmed.ncbi.nlm.nih.gov/?term=Shionoya+K&cauthor_id=43008022)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/43008022/#full-view-affiliation-2 "Department of Drug Development, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo 162-8640, Japan."), [Frank Stappenbeck](https://pubmed.ncbi.nlm.nih.gov/?term=Stappenbeck+F&cauthor_id=43008022)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/43008022/#full-view-affiliation-3 "Max BioPharma, Inc., Santa Monica, CA 90404."), [Takeshi Morita](https://pubmed.ncbi.nlm.nih.gov/?term=Morita+T&cauthor_id=43008022)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/43008022/#full-view-affiliation-2 "Department of Drug Development, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo 162-8640, Japan."), [Hirofumi Ohashi](https://pubmed.ncbi.nlm.nih.gov/?term=Ohashi+H&cauthor_id=43008022)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/43008022/#full-view-affiliation-2 "Department of Drug Development, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo 162-8640, Japan."), [Noritaka Kagaya](https://pubmed.ncbi.nlm.nih.gov/?term=Kagaya+N&cauthor_id=43008022)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/43008022/#full-view-affiliation-4 "National Institute of Advanced Industrial Science and Technology, Tokyo 135-0064, Japan."), [Makoto Nagano](https://pubmed.ncbi.nlm.nih.gov/?term=Nagano+M&cauthor_id=43008022)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/43008022/#full-view-affiliation-2 "Department of Drug Development, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo 162-8640, Japan."), [Junki Mifune](https://pubmed.ncbi.nlm.nih.gov/?term=Mifune+J&cauthor_id=43008022)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/43008022/#full-view-affiliation-2 "Department of Drug Development, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo 162-8640, Japan."), [Ryo Morishita](https://pubmed.ncbi.nlm.nih.gov/?term=Morishita+R&cauthor_id=43008022)[ 5 ](https://pubmed.ncbi.nlm.nih.gov/43008022/#full-view-affiliation-5 "Cell Free Sciences Co., Ltd., Matsuyama 790-8577, Japan."), [Feng Wang](https://pubmed.ncbi.nlm.nih.gov/?term=Wang+F&cauthor_id=43008022)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/43008022/#full-view-affiliation-3 "Max BioPharma, Inc., Santa Monica, CA 90404."), [Tetsuya Toyoda](https://pubmed.ncbi.nlm.nih.gov/?term=Toyoda+T&cauthor_id=43008022)[ 6 ](https://pubmed.ncbi.nlm.nih.gov/43008022/#full-view-affiliation-6 "Choju Medical Institute, Toyohashi 441-8124, Japan."), [Norimichi Nomura](https://pubmed.ncbi.nlm.nih.gov/?term=Nomura+N&cauthor_id=43008022)[ 7 ](https://pubmed.ncbi.nlm.nih.gov/43008022/#full-view-affiliation-7 "Department of Cell Biology, Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan.")[ 8 ](https://pubmed.ncbi.nlm.nih.gov/43008022/#full-view-affiliation-8 "Division of Systemic Life Sciences, Graduate School of Biostudies, Kyoto University, Kyoto 606-8501, Japan."), [Kazuo Shin-Ya](https://pubmed.ncbi.nlm.nih.gov/?term=Shin-Ya+K&cauthor_id=43008022)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/43008022/#full-view-affiliation-4 "National Institute of Advanced Industrial Science and Technology, Tokyo 135-0064, Japan."), [Kazuhiko Katayama](https://pubmed.ncbi.nlm.nih.gov/?term=Katayama+K&cauthor_id=43008022)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/43008022/#full-view-affiliation-1 "Graduate School of Infection Control Sciences, Kitasato University, Tokyo 108-8641, Japan."), [Farhad Parhami](https://pubmed.ncbi.nlm.nih.gov/?term=Parhami+F&cauthor_id=43008022)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/43008022/#full-view-affiliation-3 "Max BioPharma, Inc., Santa Monica, CA 90404."), [Koichi Watashi](https://pubmed.ncbi.nlm.nih.gov/?term=Watashi+K&cauthor_id=43008022)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/43008022/#full-view-affiliation-2 "Department of Drug Development, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo 162-8640, Japan.") Affiliations Expand ### Affiliations * 1 Graduate School of Infection Control Sciences, Kitasato University, Tokyo 108-8641, Japan. * 2 Department of Drug Development, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo 162-8640, Japan. * 3 Max BioPharma, Inc., Santa Monica, CA 90404. * 4 National Institute of Advanced Industrial Science and Technology, Tokyo 135-0064, Japan. * 5 Cell Free Sciences Co., Ltd., Matsuyama 790-8577, Japan. * 6 Choju Medical Institute, Toyohashi 441-8124, Japan. * 7 Department of Cell Biology, Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan. * 8 Division of Systemic Life Sciences, Graduate School of Biostudies, Kyoto University, Kyoto 606-8501, Japan. * PMID: **43008022** * DOI: [ 10.1073/pnas.2603986123 ](https://doi.org/10.1073/pnas.2603986123) Free article Item in Clipboard # Disruption of the NTCP-EGFR receptor complex as a strategy for selective inhibition of hepatitis B and D virus entry Atsuto Kusunoki et al. Proc Natl Acad Sci U S A. 2026. Free article Show details Display options Display options Format Abstract PubMed PMID Proc Natl Acad Sci U S A Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Proc+Natl+Acad+Sci+U+S+A%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Proc+Natl+Acad+Sci+U+S+A%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/43008022/) . 2026 Nov 17;123(46):e2603986123. doi: 10.1073/pnas.2603986123. Epub 2026 Nov 10. ### Authors [Atsuto Kusunoki](https://pubmed.ncbi.nlm.nih.gov/?term=Kusunoki+A&cauthor_id=43008022)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/43008022/#short-view-affiliation-1 "Graduate School of Infection Control Sciences, Kitasato University, Tokyo 108-8641, Japan.")[ 2 ](https://pubmed.ncbi.nlm.nih.gov/43008022/#short-view-affiliation-2 "Department of Drug Development, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo 162-8640, Japan."), [Kaho Shionoya](https://pubmed.ncbi.nlm.nih.gov/?term=Shionoya+K&cauthor_id=43008022)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/43008022/#short-view-affiliation-2 "Department of Drug Development, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo 162-8640, Japan."), [Frank Stappenbeck](https://pubmed.ncbi.nlm.nih.gov/?term=Stappenbeck+F&cauthor_id=43008022)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/43008022/#short-view-affiliation-3 "Max BioPharma, Inc., Santa Monica, CA 90404."), [Takeshi Morita](https://pubmed.ncbi.nlm.nih.gov/?term=Morita+T&cauthor_id=43008022)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/43008022/#short-view-affiliation-2 "Department of Drug Development, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo 162-8640, Japan."), [Hirofumi Ohashi](https://pubmed.ncbi.nlm.nih.gov/?term=Ohashi+H&cauthor_id=43008022)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/43008022/#short-view-affiliation-2 "Department of Drug Development, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo 162-8640, Japan."), [Noritaka Kagaya](https://pubmed.ncbi.nlm.nih.gov/?term=Kagaya+N&cauthor_id=43008022)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/43008022/#short-view-affiliation-4 "National Institute of Advanced Industrial Science and Technology, Tokyo 135-0064, Japan."), [Makoto Nagano](https://pubmed.ncbi.nlm.nih.gov/?term=Nagano+M&cauthor_id=43008022)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/43008022/#short-view-affiliation-2 "Department of Drug Development, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo 162-8640, Japan."), [Junki Mifune](https://pubmed.ncbi.nlm.nih.gov/?term=Mifune+J&cauthor_id=43008022)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/43008022/#short-view-affiliation-2 "Department of Drug Development, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo 162-8640, Japan."), [Ryo Morishita](https://pubmed.ncbi.nlm.nih.gov/?term=Morishita+R&cauthor_id=43008022)[ 5 ](https://pubmed.ncbi.nlm.nih.gov/43008022/#short-view-affiliation-5 "Cell Free Sciences Co., Ltd., Matsuyama 790-8577, Japan."), [Feng Wang](https://pubmed.ncbi.nlm.nih.gov/?term=Wang+F&cauthor_id=43008022)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/43008022/#short-view-affiliation-3 "Max BioPharma, Inc., Santa Monica, CA 90404."), [Tetsuya Toyoda](https://pubmed.ncbi.nlm.nih.gov/?term=Toyoda+T&cauthor_id=43008022)[ 6 ](https://pubmed.ncbi.nlm.nih.gov/43008022/#short-view-affiliation-6 "Choju Medical Institute, Toyohashi 441-8124, Japan."), [Norimichi Nomura](https://pubmed.ncbi.nlm.nih.gov/?term=Nomura+N&cauthor_id=43008022)[ 7 ](https://pubmed.ncbi.nlm.nih.gov/43008022/#short-view-affiliation-7 "Department of Cell Biology, Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan.")[ 8 ](https://pubmed.ncbi.nlm.nih.gov/43008022/#short-view-affiliation-8 "Division of Systemic Life Sciences, Graduate School of Biostudies, Kyoto University, Kyoto 606-8501, Japan."), [Kazuo Shin-Ya](https://pubmed.ncbi.nlm.nih.gov/?term=Shin-Ya+K&cauthor_id=43008022)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/43008022/#short-view-affiliation-4 "National Institute of Advanced Industrial Science and Technology, Tokyo 135-0064, Japan."), [Kazuhiko Katayama](https://pubmed.ncbi.nlm.nih.gov/?term=Katayama+K&cauthor_id=43008022)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/43008022/#short-view-affiliation-1 "Graduate School of Infection Control Sciences, Kitasato University, Tokyo 108-8641, Japan."), [Farhad Parhami](https://pubmed.ncbi.nlm.nih.gov/?term=Parhami+F&cauthor_id=43008022)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/43008022/#short-view-affiliation-3 "Max BioPharma, Inc., Santa Monica, CA 90404."), [Koichi Watashi](https://pubmed.ncbi.nlm.nih.gov/?term=Watashi+K&cauthor_id=43008022)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/43008022/#short-view-affiliation-2 "Department of Drug Development, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo 162-8640, Japan.") ### Affiliations * 1 Graduate School of Infection Control Sciences, Kitasato University, Tokyo 108-8641, Japan. * 2 Department of Drug Development, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo 162-8640, Japan. * 3 Max BioPharma, Inc., Santa Monica, CA 90404. * 4 National Institute of Advanced Industrial Science and Technology, Tokyo 135-0064, Japan. * 5 Cell Free Sciences Co., Ltd., Matsuyama 790-8577, Japan. * 6 Choju Medical Institute, Toyohashi 441-8124, Japan. * 7 Department of Cell Biology, Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan. * 8 Division of Systemic Life Sciences, Graduate School of Biostudies, Kyoto University, Kyoto 606-8501, Japan. * PMID: **43008022** * DOI: [ 10.1073/pnas.2603986123 ](https://doi.org/10.1073/pnas.2603986123) Item in Clipboard Full text links Cite Display options Display options Format Abstract PubMed PMID Linked Discoveries ## Abstract Hepatitis B and D virus (HBV, HDV) enter hepatocytes through a coordinated process mediated by a receptor complex consisting of sodium taurocholate cotransporting polypeptide (NTCP), and host entry cofactors, including epidermal growth factor receptor (EGFR). Here, we established an in vitro assay to evaluate the NTCP-EGFR interaction and identified Oxy229, an oxysterol-based compound that disrupted this molecular interaction. Oxy229 selectively inhibited HBV and HDV infection to HepG2-NTCP cells and primary human hepatocytes. Mechanistic analysis revealed that Oxy229 impaired the relocalization of HBV-NTCP complex from the plasma membrane to intracellular vesicles. Notably, Oxy229 did not compromise the physiological functions of NTCP and EGFR, i.e., bile acid transporter and activation of downstream EGFR signaling pathways including Ras-MAPK and PI3K-Akt pathways, indicating selective inhibition of viral entry. Compound derivative analysis identified Oxy283, which acquired dual inhibitory activity against both NTCP-EGFR interaction and NTCP multimerization, resulting in enhanced anti-HBV potency. These findings establish the f
## Related Clinical Research

- [Hepatitis C treatment access in Los Angeles County: barriers, facilitators, and linkage-to-cure fi](https://medichelpline.com/clinical-feed/plos-one-9-exploring-barriers-and-facilitators-to-hepatitis-c-virus-treatment-access-in.md)
- [HPV prevalence and genotype distribution in women from northern Lao PDR (2018–2019)](https://medichelpline.com/clinical-feed/plos-one-15-prevalence-and-genotype-distribution-of-human-papillomavirus-in-women-from.md)
- [NOX2 drives HBV replication via ROS-induced autophagy in cell models](https://medichelpline.com/clinical-feed/pubmed-43059380.md) (DOI: 10.3892/ijmm.2026.6054)
- [Continuous luminescence monitoring of hepatitis C virus and orthoflavivirus infections](https://medichelpline.com/clinical-feed/pubmed-42861980.md) (DOI: 10.1128/jvi.01266-26)
- [Sentinel Surveillance Identifies Threats to SMC Effectiveness in Northern Kenya](https://medichelpline.com/clinical-feed/medrxiv-2-sentinel-event-surveillance-to-identify-threats-to-smc-effectiveness.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.